Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/197180
Title: | Allergen sensitization stratifies IL-31 production by memory T cells in atopic dermatitis patients |
Author: | Sans de San Nicolàs, Lídia Figueras Nart, Ignasi García-Jiménez, Irene Bonfill Ortí, Montserrat Guilabert, Antonio Curto Barredo, Laia Bertolín Colilla, Marta Ferran, Marta Serra Baldrich, Esther Pujol, Ramon M. Santamaria Babí, Luis F. |
Keywords: | Dermatitis atòpica Al·lèrgens Citocines Cèl·lules T Atopic dermatitis Allergens Cytokines T cells |
Issue Date: | 13-Mar-2023 |
Publisher: | Frontiers Media SA |
Abstract: | Background:The role of allergen sensitization in IL-31 production by T cells and specifically in the clinical context of atopic dermatitis (AD) has not been characterized. MethodsThe response to house dust mite (HDM) in purified memory T cells cocultured with epidermal cells from AD patients (n=58) and control subjects (n=11) was evaluated. AD-associated cytokines from culture supernatants, plasma proteins and mRNA expression from cutaneous lesions were assessed and related with the clinical features of the patients. ResultsHDM-induced IL-31 production by memory T cells defined two subsets of AD patients according to the presence or absence of IL-31 response. Patients in the IL-31 producing group showed a more inflammatory profile, and increased HDM-specific (sp) and total IgE levels compared to the IL-31 non-producing group. A correlation between IL-31 production and patient's pruritus intensity, plasma CCL27 and periostin was detected. When the same patients were analyzed based on sp IgE and total IgE levels, an increased IL-31 in vitro response, as well as type 2 markers in plasma and cutaneous lesions, was found in patients with sp IgE levels > 100 kUA/L and total IgE levels > 1000 kU/L. The IL-31 response by memory T cells was restricted to the cutaneous lymphocyte-associated antigen (CLA)(+) T-cell subset. ConclusionIgE sensitization to HDM allows stratifying IL-31 production by memory T cells in AD patients and relating it to particular clinical phenotypes of the disease. |
Note: | Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2023.1124018 |
It is part of: | Frontiers in Immunology, 2023, vol. 14, num. 1124018 |
URI: | https://hdl.handle.net/2445/197180 |
Related resource: | https://doi.org/10.3389/fimmu.2023.1124018 |
ISSN: | 1664-3224 |
Appears in Collections: | Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fimmu-14-1124018.pdf | 2.92 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License